joimax® Growth Trend Continues, Fuelled by Global Adoption of its Procedures

Endoscopic minimally invasive spinal surgery expert company, German-based joimax®, has announced record sales figures for 2016, 31% up on prior year.


Founded in Karlsruhe, Germany, in 2001, joimax® is the leading developer and marketer of complete systems for endoscopic minimally invasive spinal surgery.

joimax® technologies are based on worldwide intellectual property and the company holds now more than 150 patents and trademarks. In 2016 18 patents and patent publications were issued to the company. joimax is busy inventing and innovating its next minimally invasive systems that will include newer implants based on the EndoLIF® technology as well as decompression methods based on its endoscopic systems. This will be completed with Intracs®, the new Interaoperative Navigation Tracking & Control System, which joimax® instruments can be navigated directly at the tip. The Intracs ® Navigation and Monitor Unit is integrated in the joimax® Endoscopic Tower and all necessary tools are tailored for the TESSYS® (transforaminal) and iLESSYS® (interlaminar) procedures as well as for minimally invasive stabilization procedures, like EndoLIF® (Lumbar Interbody Fusion) and Percusys® (Percutaneous Screw-Rod Stabilization).

joimax’s sales growth in 2016 is in line with a Compound Annual Growth Rate (CAGR) from 2007 – 2016 of around 32%. Projections into 2017 show accelerated growth due to the worldwide increasing adoption rate of joimax® procedures.

joimax® is active in 45 countries and enjoys a strong reputation in Europe and Asia and is now serving the U.S. market as well.

Company comments

“The entry in force of the CPT 2017 reimbursement Codebook (Current Procedural Terminology) as of January 1 2017 is a milestone towards the full acceptance of endoscopic minimally invasive spine surgery techniques. The codebook now contains the first endoscopic spinal surgery code, under which the specific transforaminal (TESSYS®) and/or interlaminar (iLESSYS®) procedures marketed by joimax® are now eligible in the U.S. This will further contribute to fully increase sales in the U.S. as well,” states Wolfgang Ries, Founder and CEO of joimax®.

Source: joimax

Share your thoughts

Your email address will not be published. Required fields are marked *